Medicenna Therapeutics (MDNAF) Stock Price, News & Analysis

Company Overview

Medicenna Therapeutics Corp. is a Canadian clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company uses its proprietary Superkine platform to engineer cytokine-based medicines designed to stimulate or direct immune responses against tumors while potentially reducing some of the limitations associated with naturally occurring cytokines.

Its lead program, MDNA11, is an engineered interleukin-2 (IL-2) super-agonist intended to activate cancer-fighting immune cells and is being evaluated in clinical studies for advanced solid tumors. Medicenna has also developed MDNA55, an IL-4–targeted fusion protein designed to deliver a cell-killing payload to tumors that express the interleukin-4 receptor, including recurrent glioblastoma. The company’s development activities have included clinical research in North America and collaborations with academic and clinical institutions.

Medicenna was founded in Canada and is headquartered in Toronto, Ontario. The company is led by Fahar Merchant, who serves as president and chief executive officer and is one of its founders. Medicenna’s shares trade in the United States under the symbol MDNAF.

Key Stats

• Today's Range: $0.24 to $0.31
• 50-Day Range: $0.24 to $0.35
• 52-Week Range: $0.23 to $1.43
• Volume: 34,531 shs
• Average Volume: 31,884 shs
• Market Capitalization: $28.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Medicenna Therapeutics Stock Analysis - MarketRank™

Medicenna Therapeutics scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Medicenna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Medicenna Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Medicenna Therapeutics are expected to grow in the coming year, from ($0.17) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medicenna Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medicenna Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medicenna Therapeutics has a P/B Ratio of 15.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.83% of the float of Medicenna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Medicenna Therapeutics has a short interest ratio ("days to cover") of 6.79.

Change versus previous month

Short interest in Medicenna Therapeutics has recently increased by 4.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medicenna Therapeutics does not currently pay a dividend.

Dividend Growth

Medicenna Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.85% of the stock of Medicenna Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 6/25/2026
• Today: 9/19/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MDNAF
• CIK: 1807983
• Web: www.medicenna.com
• Phone: (416) 648-5555
• Fax: 416-572-7501
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1.04%
• Return on Assets: -0.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.52
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 15.25

Miscellaneous

• Outstanding Shares: 92,300,000
• Free Float: 61,749,000
• Market Cap: $28.15 million
• Optionable: N/A
• Beta: 1.83